. 2020 Sep 19;95(12):1562–1571. doi: 10.1002/ajh.25994

TABLE 1.

Associations between CG11q ^a subgroup and clinical findings

	All cases (n = 794)		CG11q ^a cases (n = 271)		Non‐CG11q ^a cases (n = 523)
Variable	n/N		n/N		n/N
Female gender	373/794	47%	106/271	39% ^*	267/523	51% ^*
Age (≥65 y) ^b	536/794	68%	187/271	69%	349/523	67%
BM plasma cell (≥60%) ^b	175/754	23%	50/253	20%	125/501	25%
Samples from pretreated patients	135/794	17%	48/271	18%	87/523	17%
MACS enriched samples	344/794	43%	118/271	44%	226/523	43%
IgG	203/365	56%	84/127	66% ^*	119/238	50% ^*
IgA	81/365	22%	28/127	22%	53/238	22%
Light chain only	76/365	21%	15/127	12% ^*	61/238	26% ^*
Other ^c	4/365	1%	0/127	0%	4/238	2%
Kappa	239/370	65%	89/125	71%	150/245	61%
Lambda	127/370	34%	36/125	29%	91/245	37%
LDH (increased)	61/264	23%	15/87	17%	46/177	26%
Creatinine (≥2 mg/dL)	46/273	17%	15/92	16%	31/181	17%
B2M (≥5.5 mg/L)	74/247	30%	19/80	24%	55/167	33%
Hemoglobin (<10 g/dL)	85/247	34%	25/79	32%	60/168	36%
Platelets (<150 x 10⁹/L)	57/249	23%	17/79	22%	40/170	24%
Calcium (≥2.75 mmol/L)	17/260	7%	5/88	6%	12/172	7%
Serum involved/uninvolved FLC ratio (≥100)	91/222	41%	31/76	41%	60/146	41%
ISS I	66/236	28%	26/77	34%	40/159	25%
ISS II	96/236	41%	31/77	40%	65/159	41%
ISS III	74/236	31%	20/77	26%	54/159	34%
R‐ISS I	42/219	19%	18/69	26%	24/150	16%
R‐ISS II	144/219	66%	46/69	67%	98/150	65%
R‐ISS III	33/219	15%	5/69	7%	28/150	19%
PI‐based induction	123/311	40%	45/107	42%	78/204	38%
IMiD‐based induction	14/311	5%	7/107	7%	7/204	3%
PI‐based and IMiD‐based induction	165/311	53%	52/107	49%	113/204	55%
Other ^d	9/311	3%	3/107	3%	6/204	3%
Maintenance	111/287	39%	40/101	40%	71/186	38%
Front‐line ASCT	135/307	44%	51/104	49%	84/203	41%
EMM ^e	52/328	16%	15/111	14%	37/217	17%
PCL ^f	24/328	7%	3/111	3%	21/217	10%
AL	14/323	4%	4/110	4%	10/213	5%

Note: Clinical features at diagnosis, unless otherwise indicated. All statistically significant values are in bold.

Abbreviations: AL, Amyloidosis; ASCT, autologous stem cell transplantation; B2M, beta‐2 microglobulin; BM, bone marrow; FLC, free light chain; IMiD, immunomodulatory drugs; ISS, International Staging System; LDH, lactate dehydrogenase; MACS, magnetic‐activated cell sorting; PI, proteasome inhibitors; R‐ISS, revised International Staging System.

^{^a}

Subgroup clonal gain(11q) (CG11q) was defined as the presence of clonal gain(11q) and the absence of t(4;14), t(11;14), and t(14;16).

^{^b}

Clinical feature the time of first sampling.

^{^c}

This category includes IgD, IgM, and nonsecretory MM.

^{^d}

This category includes alkylating agents and monoclonal antibodies.

^{^e}

Extramedullary myeloma (EMM) was present at diagnosis or developed during disease course and was defined as plasma cell infiltration of the soft tissue (extramedullary extraosseous and/or extramedullary‐bone related).

^{^f}

Plasma cell leukemia (PCL) was present at diagnosis or developed during disease course.

P < .05, two‐sided Fisher's exact test. For multiple testing P values were adjusted with the Benjamini‐Hochberg method.